文献速递神经眼科眼整形与眼眶

免疫检查点抑制剂相关神经眼科传出系统免疫相关不良事件的表现、防治研究进展

[Research progress on the manifestations prevention and treatment of immune-related adverse events in the neuro-ophthalmic efferent system related to immune checkpoint inhibitors].
PubMed 文献 · Zhonghua Yan Ke Za Zhi · 2025-01-01

本综述总结免疫检查点抑制剂(ICI)相关神经眼科传出系统免疫相关不良事件(irAE)的发生机制、临床特征及防治措施。已报道的类型主要包括重症肌无力、眼眶眼外肌炎、类甲状腺相关眼病、核间性眼肌麻痹、Miller-Fisher综合征及颅神经不良事件,旨在帮助眼科与肿瘤科医生早期诊断和管理此类患者。

要点

  • ICI相关神经眼科传出系统irAE较皮肤、胃肠道irAE罕见。
  • 已报道类型包括重症肌无力、眼眶眼外肌炎、类甲状腺相关眼病、核间性眼肌麻痹、Miller-Fisher综合征及颅神经不良事件。
  • 综述旨在总结发生机制、临床特征及防治措施,助眼科与肿瘤科医生早期诊断和管理。

核心结论

  • 探讨神经眼科传出系统irAE的可能机制及潜在干预措施对预测患者irAE风险、制定预防措施和实施更有效临床治疗至关重要。

研究设计与样本

  • 本文为综述,旨在总结神经眼科传出系统irAE的发生机制、临床特征及防治措施。

主要发现

  • 接受ICI治疗的部分患者可能遭受irAE影响。
  • 相较于皮肤组织、胃肠道系统等的irAE,神经眼科传出系统的irAE较为罕见。
  • 已报道的神经眼科传出系统irAE主要包括重症肌无力、眼眶眼外肌炎、类甲状腺相关眼病、核间性眼肌麻痹、Miller-Fisher综合征、颅神经不良事件。

临床怎么用

  • 本综述旨在助眼科医生和肿瘤科医生早期诊断和管理神经眼科传出系统irAE患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors (ICI), as a new type of targeted therapeutic drugs, have demonstrated durable efficacy in cancer treatment. However, some patients receiving ICI treatment may be affected by immune-related adverse events (irAE). Compared with irAE in skin tissues, gastrointestinal system, etc., irAE in the neuro-ophthalmic efferent system are relatively rare. The reported irAE in the neuro-ophthalmic efferent system mainly include myasthenia gravis, orbital extraocular myositis, thyroid-associated ophthalmopathy-like conditions, internuclear ophthalmoplegia, Miller-Fisher syndrome, and cranial nerve adverse events. Exploring the possible mechanisms and potential intervention measures of irAE in the neuro-ophthalmic efferent system is crucial for predicting the risk of irAE in patients, formulating preventive measures, and implementing more effective clinical treatments. This review aims to summarize the occurrence mechanisms, clinical features, and prevention and treatment measures of irAE in the neuro-ophthalmic efferent system, so as to assist ophthalmologists and oncologists in the early diagnosis and management of such patients. 免疫检查点抑制剂(ICI)作为一种新型靶向治疗药物,在癌症治疗中展示出持久的疗效。然而,部分接受ICI治疗的患者可能会遭受免疫相关不良事件(irAE)的影响。相较于皮肤组织、胃肠道系统等的irAE,神经眼科传出系统的irAE则较为罕见。已报道的神经眼科传出系统irAE主要包括重症肌无力、眼眶眼外肌炎、类甲状腺相关眼病、核间性眼肌麻痹、Miller-Fisher综合征、颅神经不良事件。探讨神经眼科传出系统irAE的可能机制及潜在干预措施对于预测患者irAE风险、制定预防措施以及实施更为有效的临床治疗至关重要。本综述旨在总结神经眼科传出系统irAE的发生机制、临床特征及防治措施,以助于眼科医生和肿瘤科医生早期诊断和管理此类病患。.

来源:Zhonghua Yan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Jin M, Jiang LB. [Research progress on the manifestations prevention and treatment of immune-related adverse events in the neuro-ophthalmic efferent system related to immune checkpoint inhibitors]. Zhonghua Yan Ke Za Zhi. 2025. PMID: 39743697. doi:10.3760/cma.j.cn112142-20240117-00030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。